Business Context and Reporting Period
This Form 8-K was filed by India Globalization Capital, Inc. (OTC.PK: IGCC) on November 6, 2018. The filing addresses two primary events: the delisting of the company's common stock from the NYSE AMERICAN Exchange and the receipt of a U.S. patent for a cannabinoid-based treatment.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses on corporate events rather than financial performance.
Material Changes
- Delisting and Trading Transfer: Following a suspension of trading on the NYSE AMERICAN Exchange, the company's shares will now trade on the OTC Markets – OTC Pink Tier under the symbol IGCC while the company appeals the Exchange's decision.
- Intellectual Property: The company received notification from the United States Patent and Trademark Office (USPTO) of the issuance of Patent #10,117,891. This patent covers a cannabinoid method and composition for treating pain in patients with Psoriatic Arthritis, Fibromyalgia, Scleroderma, and other conditions. The application (IGC-501) was originally filed on September 16, 2015.
Guidance, Outlook, and Risks
Management included a "Safe Harbor" statement regarding forward-looking statements, noting that success is highly correlated with product candidates. Key risks and contingencies identified include:
- Inability to adequately protect intellectual property or receive necessary patents.
- Potential failure to receive regulatory approval for products or clinical trials.
- Insufficient financial resources to conduct requisite trials.
- Challenges in commercializing products even if regulatory approval is obtained.
- Uncertainty regarding stable pricing projections over the next several years.
Investor Verification Checklist
- Verify the current trading status and liquidity of IGCC on the OTC Pink Tier.
- Confirm the scope and enforceability of Patent #10,117,891 regarding the specific cannabinoid composition.
- Review the company's current cash position to assess its ability to fund clinical trials and the appeal process for the NYSE AMERICAN delisting.
- Monitor the status of the appeal against the NYSE AMERICAN delisting decision.